STEVEN BRIA: Open Payments
NPI 1215672308 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,153 in 51 payments from 13 companies in 2025. Trend: 2023 $1,487 · 2024 $1,990 · 2025 $1,153
Food & beverage: $1,153
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $211 |
| Neurocrine BioSciences, Inc. | 6 | $157 |
| Lundbeck LLC | 7 | $155 |
| Janssen Pharmaceuticals, Inc | 5 | $127 |
| E.R. Squibb & Sons, L.L.C. | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| Alkermes, Inc. | 2 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| ABBVIE INC. | 3 | $47 |
Products named: REXULTI, INGREZZA, INVEGA SUSTENNA, ABILIFY MAINTENA, COBENFY, Auvelity, UZEDY, ABILIFY ASIMTUFII.
Industry payments across AL — which companies pay providers there.
